Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advanced renal cell carcinoma.

B G Redman1, A E Chang

  • 1University of Michigan Medical Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109-7376, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary

For advanced renal cell carcinoma, high-dose interleukin-2 (IL-2) offers palliative treatment, but its toxicity limits eligibility. Investigational immunotherapies and clinical trials for novel agents are crucial options for patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of gene gun for genetic immunotherapy : in vitro and in vivo methods.

Methods in molecular medicine·2012
Same author

Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression.

Cancer gene therapy·2008
Same author

Antitumor reactivity of lymph node cells primed in vivo with dendritic cell-based vaccines.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2002
Same author

Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.

Cancer research·2001
Same author

Tumor-specific responses in lymph nodes draining murine sarcomas are concentrated in cells expressing P-selectin binding sites.

Journal of immunology (Baltimore, Md. : 1950)·2001
Same author

Treating colon cancer with a melanoma vaccine? Preposterous?

Annals of surgical oncology·2001

Area of Science:

  • Oncology
  • Immunology
  • Urology

Background:

  • Advanced renal cell carcinoma treatment is largely palliative.
  • Standard chemotherapy is ineffective for this cancer.
  • High-dose interleukin-2 (IL-2) is the only established effective treatment, but has significant toxicity.

Purpose of the Study:

  • To review the current treatment landscape for advanced renal cell carcinoma.
  • To highlight the limitations of existing therapies.
  • To discuss the role of investigational approaches.

Main Methods:

  • Literature review of advanced renal cell carcinoma treatment options.
  • Analysis of efficacy and toxicity of high-dose IL-2.
  • Overview of current investigational strategies, including immunotherapies and novel agents.

Main Results:

  • High-dose IL-2 shows benefit in a minority of eligible patients (15-20% response rate, 7% long-term complete response).
  • Toxicity limits the use of high-dose IL-2.
  • Investigational immunotherapies are a primary focus for new treatments.

Conclusions:

  • Effective treatment options for advanced renal cell carcinoma are limited.
  • High-dose IL-2 remains a key, albeit restricted, therapeutic option.
  • Clinical trial participation in novel cytotoxic or antiangiogenic agents is an important alternative for patients.

Related Experiment Videos